Hannah Clarke

Sima P. Porten, MD, MPH, discusses the need to better understand how genetic makeup influences how individuals process environmental toxins.

“I think it will help patients decide what prostate surgery they want,” says Naeem Bhojani, MD, FRCSC.

“The technology in the field of stone management is exciting, and I think it offers patients a lot more options than what they've had in the past,” says Brian Stork, MD.

An approach to WVTT involving 1 treatment per prostate lobe was associated with decreased post-operative complications.

"What we found is that 9% of women with a GSM-related diagnosis filled a prescription for vaginal estrogen during the study period, and these women tended to be younger," says Ekene Enemchukwu, MD, MPH, FACS, URPS.

This approval marks the first clearance of a stapler designed for single-port robotic surgery in the US.

"Building on decades of research into the genetic markers of prostate cancer, our study shows that the theory does work in practice—we can identify men at risk of aggressive cancers who need further tests and spare the men who are at lower risk from unnecessary treatments," says professor Ros Eeles.

Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology.

"We should not be preemptively reducing the dose for all our patients, because half of the patients will never develop grade 3/4 anemia," says Neeraj Agarwal, MD, FASCO.

In February 2025, the FDA recommended a removal of the black box warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products. This recommendation has important implications for urologists and the patients they treat.

“I think it's primarily due to dietary changes that are more and more prevalent regardless of sex,” says Ian Metzler, MD, MTM.

At week 12, patients in the URO-902 cohorts demonstrated significantly greater improvements in daily microuritions vs placebo.

"“The approval of Gozellix is likely to both streamline and expand access to PSMA-PET imaging, hopefully broadening the distribution and use of gallium 68," says Kelly L. Stratton, MD, FACS.

"For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR.

"This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.

“To find a therapy that's all encompassing, that manages all of this in a long-term fashion, low-dose vaginal estrogen is the preferred treatment,” says Ekene Enemchukwu, MD, MPH, FACS, URPS.

A lookahead of the notable FDA decisions and conferences slated for Q2 2025.

"This study was an investigator initiated study, and what they wanted to do was a randomized trial for large prostates, so 80 to 180 grams, between Aquablation and prostate enucleation," says Naeem Bhojani, MD, FRCSC.

"This is another tool in our armamentarium to treat muscle-invasive bladder cancer and represents an advance compared to where we've been over the past few decades," says Matthew D. Galsky, MD.

“The differences in patient experience between UroLift System and Rezūm, particularly in terms of early recovery, sexual function, and overall satisfaction, are key considerations for both clinicians and patients selecting a treatment path," says Mark Rochester, MD, FRCS.

"We demonstrate that patients with metastatic disease stayed on therapy longer—a median of 9 months vs 7 months for the non-metastatic patients," says Rana R. McKay, MD, FASCO.

"We have communicated with Solventum, who makes this software, and they have made changes based on our feedback," says Timothy D. Lyon, MD.

"The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.

"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall survival is about 45 to 47 months," says Neeraj Agarwal, MD, FACS.

The company plans to initiate the phase 2 monotherapy trial by mid-year.

"I think AI is going to have a significant role. We're just at the tip of the iceberg," says Jason M. Hafron, MD, CMO.

"They are risking their own lives for their job, so it's the part of the whole community to do our best to try to keep them safe," says Sima P. Porten, MD, MPH.

"Glean will enable patients to void naturally, without catheters in place. I believe this advance will yield a better test that mimics actual symptoms," says Bilal I. Chughtai, MD.

“The data presented at EAU25 add to the growing body of evidence supporting the CVAC System as the emerging standard of care in kidney stone removal,” says Brett Johnson, MD.

“If it is as efficacious as it looks, we will have more patients who are getting effective standard of care treatment, not needing to go on to further treatment, not having recurrences, [having decreased] morbidity from repeated resections, and saving bladders in the process," says Eugene B. Cone, MD.